Skip to main content
. 2014 Jun 15;7(7):3632–3646.

Table 3.

Summarized Univariate HR of overall and subgroup analyses for CD44v6 on NSCLC survival

N. of studies Number of patients Random effects HR (95% CIs) Heterogeneity test

chi-squared I2 P-value
Written Language
    English written 5 0.88 (0.47-1.63) 13.6 70.60% 0.678
    Non English written 10 2.05 (1.59-2.64) 28.1 67.90% 0.0001
HR Estimate
    HR 2 0.73 (0.16-2.3) 9.58 89.6 0.683
    Sur. Curve 13 1.83 (1.26-2.65) 62.14 82.3 0.001
Ethnicity
    Asian 13 1.78 (1.34-2.35) 48.26 75.10% 0.0001
    Non-Asian 2 0.53 (0.29-2.92) 3.24 69.20% 0.892
Cutoff value
    0% 6 1.31 (0.73-2.35) 23.54 78.80% 0.369
    10% 4 2.03 (0.79-5.22) 43.56 93.10% 0.141
Tumor stage
    I-II 5 1.78 (0.78-4.09) 23.85 83.20% 0.7114
    I-III 7 1.61 (1.01-2.58) 43.52 86.20% 0.0400
Follow up time
    36 months 4 1.79 (0.9-3.58) 12.05 75.10% 0.0035
    60 months 9 1.82 (1.29-2.56) 35.88 77.70% 0.1915